IN8bio, Inc. INAB

INAB Company Overview

IN8bio, Inc. is a clinical-stage biotechnology company focused on developing gamma-delta T cell-based immunotherapies for cancer and other difficult-to-treat diseases. The company operates within the biotechnology and cell therapy industries, with research centered on leveraging the immune system’s innate and adaptive capabilities to target tumors. IN8bio’s primary development programs involve allogeneic and autologous gamma-delta T cell therapies intended for hematologic malignancies and solid tumors, including glioblastoma and acute leukemia. Its core revenue activity currently derives from research and development operations rather than commercial product sales, as the company remains in the clinical development stage.

The company traces its origins to work conducted around gamma-delta T cell biology and was incorporated as IN8bio before becoming publicly traded on the Nasdaq under the ticker INAB. IN8bio has positioned itself around proprietary approaches designed to enhance the persistence and tumor-targeting activity of gamma-delta T cells while potentially reducing graft-versus-host disease risks associated with certain conventional cell therapies. The company’s strategy emphasizes differentiated immunotherapy platforms targeting areas with high unmet medical need.